Take-home’ message for the clinician
Lung cancer continues to be the leading cause of cancer deaths. The molecular landscape of lung canceris rapidly evolving leading to a paradigm shift in the management ofadvanced non-small cell lung cancer. The new therapeutic regimens are primarily designed to use target therapies, mainly tyrosine kinase inhibitorsin patients with targeted mutations and immunotherapies (with or without chemotherapy) in patients without driver mutations. Both novel treatments have lesser toxicities and better safety profile compared to chemotherapeutic agents.